A communication from the Executive Office of Health and Human Services (see item 4000-0300 contained in Section 2 of Chapter 28 of the Acts of 2023) submitting its quarterly MassHealth Pharmacy Pipeline Report for April 1, 2024-March 31, 2025

This document is a formal report submitted by the Massachusetts Executive Office of Health and Human Services to state legislative committees regarding MassHealth pharmacy costs. It details the projected expenses for 68 new pharmaceutical products expected to become available between April 1, 2024, and March 31, 2025, estimating a total cost of approximately $13.9 million. The report highlights that cell and gene therapies account for about 70% of this spending, noting a decrease from the previous quarter's estimate due to the approval of two specific gene therapies.